Cargando…

Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53

Previously, our group demonstrated that nuclear expression of E3 ubiquitin ligase (MDM2) in malignant pleural mesothelioma (MPM) is significantly associated with decreased overall survival. A possible explanation may be that overexpression of MDM2 leads to a proteasomal degradation of TP53 that even...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walter, Robert F. H., Werner, Robert, Wessolly, Michael, Mairinger, Elena, Borchert, Sabrina, Schmeller, Jan, Kollmeier, Jens, Mairinger, Thomas, Hager, Thomas, Bankfalvi, Agnes, Christoph, Daniel C., Eberhardt, Wilfried E. E., Plönes, Till, Aigner, Clemens, Schmid, Kurt W., Wohlschlaeger, Jeremias, Mairinger, Fabian D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077509/ https://www.ncbi.nlm.nih.gov/pubmed/30112000 http://dx.doi.org/10.1155/2018/1986982

Ejemplares similares

Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy
por: Mairinger, Fabian D., et al.
Publicado: (2018)

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro
por: Borchert, Sabrina, et al.
Publicado: (2019)

Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma
por: Borchert, Sabrina, et al.
Publicado: (2020)

One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy
por: Hager, Thomas, et al.
Publicado: (2023)

Screening of Pleural Mesothelioma Cell Lines for Kinase Activity May Identify New Mechanisms of Therapy Resistance in Patients Receiving Platin-Based Chemotherapy
por: Borchert, Sabrina, et al.
Publicado: (2019)

microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma
por: Walter, Robert Fred Henry, et al.
Publicado: (2016)

Mitogen signal-associated pathways, energy metabolism regulation, and mediation of tumor immunogenicity play essential roles in the cellular response of malignant pleural mesotheliomas to platinum-based treatment: a retrospective study
por: Mathilakathu, Alexander, et al.
Publicado: (2021)

Cancer-Associated Fibroblasts Influence Survival in Pleural Mesothelioma: Digital Gene Expression Analysis and Supervised Machine Learning Model
por: Borchert, Sabrina, et al.
Publicado: (2023)

Induction of metallothionein expression by supplementation of zinc induces resistance against platinum-based treatment in malignant pleural mesothelioma
por: Wyrich, Martine, et al.
Publicado: (2023)

Processing Escape Mechanisms Through Altered Proteasomal Cleavage of Epitopes Affect Immune Response in Pulmonary Neuroendocrine Tumors
por: Wessolly, Michael, et al.
Publicado: (2018)

Digital Gene Expression Analysis of Epithelioid and Sarcomatoid Mesothelioma Reveals Differences in Immunogenicity
por: Brcic, Luka, et al.
Publicado: (2021)

MDM2 is an important prognostic and predictive factor for platin–pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53
por: Walter, R F H, et al.
Publicado: (2015)

Bortezomib sensitivity is tissue dependent and high expression of the 20S proteasome precludes good response in malignant pleural mesothelioma
por: Walter, Robert Fred Henry, et al.
Publicado: (2019)

Cancer-Associated Fibroblasts Regulate Kinase Activity in Mesothelioma Cell Lines via Paracrine Signaling and Thereby Dictate Cell Faith and Behavior
por: Mathilakathu, Alexander, et al.
Publicado: (2022)

Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy
por: Walter, Robert Fred Henry, et al.
Publicado: (2016)

Fibroblast activation protein-α expression in fibroblasts is common in the tumor microenvironment of colorectal cancer and may serve as a therapeutic target
por: Greimelmaier, K., et al.
Publicado: (2023)

Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma
por: Mairinger, Fabian Dominik, et al.
Publicado: (2017)

CAF-Associated Paracrine Signaling Worsens Outcome and Potentially Contributes to Chemoresistance in Epithelial Ovarian Cancer
por: Wessolly, Michael, et al.
Publicado: (2022)

A Novel Epitope Quality-Based Immune Escape Mechanism Reveals Patient’s Suitability for Immune Checkpoint Inhibition
por: Wessolly, Michael, et al.
Publicado: (2020)

Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy
por: Wessolly, Michael, et al.
Publicado: (2022)

Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma
por: Mairinger, Elena, et al.
Publicado: (2023)

ACTB, CDKN1B, GAPDH, GRB2, RHOA and SDCBP Were Identified as Reference Genes in Neuroendocrine Lung Cancer via the nCounter Technology
por: Walter, Robert Fred Henry, et al.
Publicado: (2016)

Massive parallel sequencing and digital gene expression analysis reveals potential mechanisms to overcome therapy resistance in pulmonary neuroendocrine tumors
por: Walter, Robert Fred Henry, et al.
Publicado: (2016)

Digital Immune-Related Gene Expression Signatures In High-Grade Serous Ovarian Carcinoma: Developing Prediction Models For Platinum Response
por: Mairinger, Fabian, et al.
Publicado: (2019)

Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome
por: Henry Walter, Robert Fred, et al.
Publicado: (2016)

Structure of a Stapled Peptide Antagonist Bound to Nutlin-Resistant Mdm2
por: Chee, Sharon Min Qi, et al.
Publicado: (2014)

Integrated Clinical, Molecular and Immunological Characterization of Pulmonary Sarcomatoid Carcinomas Reveals an Immune Escape Mechanism That May Influence Therapeutic Strategies
por: Stephan-Falkenau, Susann, et al.
Publicado: (2023)

Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group
por: Vollbrecht, Claudia, et al.
Publicado: (2015)

Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
por: Yee-Lin, Voon, et al.
Publicado: (2018)

Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours
por: Mairinger, Fabian Dominik, et al.
Publicado: (2014)

Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists
por: Urso, Loredana, et al.
Publicado: (2017)

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63
por: Gamble, Laura D., et al.
Publicado: (2011)

The Pharmacodynamics of the p53-Mdm2 Targeting Drug Nutlin: The Role of Gene-Switching Noise
por: Puszynski, Krzysztof, et al.
Publicado: (2014)

Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3
por: Yang, Peipei, et al.
Publicado: (2016)

Acceptance of Telepathology in Daily Practice
por: Mairinger, Thomas
Publicado: (2000)

Identification of deregulation of apoptosis and cell cycle in neuroendocrine tumors of the lung via NanoString nCounter expression analysis
por: Walter, Robert Fred Henry, et al.
Publicado: (2015)

Proteasomal Processing Immune Escape Mechanisms in Platinum-Treated Advanced Bladder Cancer
por: Wessolly, Michael, et al.
Publicado: (2022)

Correction: The Pharmacodynamics of the p53-Mdm2 Targeting Drug Nutlin: The Role of Gene-Switching Noise
Publicado: (2015)

MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
por: Ohnstad, Hege O, et al.
Publicado: (2011)

Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3
por: Huang, Baoying, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ppu77rc50k77bcg5bdgvfbj2o4